Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK, Safety, and PD of OPC-61815 in Healthy Chinese Males
NCT05439148Phase 1Completed
- Sponsor
- Otsuka Holdings
- Start
- Jun 2022
- Primary completion
- Sep 2022
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tolvaptan sodium phosphate in edema secondary to heart failure and heart failure (HF) (2 arms), sponsored by Otsuka Holdings. Primary endpoints: Time to Maximum Plasma Concentration at Day 9, Maximum Plasma Concentration at Day 9 and 6 more. Started Jun 2022; status: completed.
02
Drugs
tolvaptan sodium phosphate
03
Conditions
edema secondary to heart failureheart failure (HF)
Beyond the preview
Go deeper on NCT05439148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05439148.